Business
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
BOSTON, May 07, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance.
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year –","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"– Total revenue of $107 million, GAAP net income of $41 million and adjusted EBITDA of $77 million in Q1 2026 –","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"– On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026 –","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"– sNDA for LINZESS treatment of functional constipation (FC) in patients 2 to 5 years of age accepted and granted priority review by FDA; PDUFA date set for May 24th –","length":167,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 07, 2026--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance.","length":307,"tagName":"p"},{"type":"text","content":""Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-year 2026 financial guidance," said Tom McCourt, chief executive officer of Ironwood. "We expect strong first quarter revenue to result in significant operating cash flows in the second quarter of 2026, which will help support repayment of our 2026 convertible notes at maturity in June."","length":512,"tagName":"p"},{"type":"text","content":""We remain on track for site initiation for the confirmatory STARS‑2 Phase 3 clinical trial in the second quarter," said Michael Shetzline, chief medical officer, senior vice president and head of research and drug development at Ironwood. "Building on the positive results from STARS, we believe that the highly potent, selective, and long-acting pharmacologic properties of apraglutide have the potential to drive best-in-class efficacy and tolerability with once-weekly dosing and redefine the standard of care in SBS-IF. Importantly, the long-te...